News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The launch of HULIO in the United States is an important milestone for Biocon Biologics
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Subscribe To Our Newsletter & Stay Updated
